Keppra (Levetiracetam)

Levetiracetam binds selectively to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. By stabilizing synaptic vesicle function, it reduces excessive neuronal firing and diminishes excitatory transmission, thereby lowering the likelihood of seizure generation without directly affecting GABA or glutamate receptors.

The dosage of Keppra is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. The prescriber determines the appropriate loading dose and maintenance regimen, which may be adjusted over time to achieve optimal seizure control.

Keppra is classified as pregnancy category B, indicating that animal studies have not shown risk and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies the potential risk. Limited data suggest it is excreted in breast milk, so breastfeeding decisions should be made in consultation with a healthcare professional.

To request Keppra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Compared with traditional antiepileptics such as carbamazepine or phenytoin, levetiracetam has a distinct mechanism targeting SV2A and generally fewer drug‑enzyme interactions. This can result in a more predictable pharmacokinetic profile and a lower likelihood of hepatic toxicity, though individual response and tolerability vary among patients.

Keppra injection should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Keppra is supplied as a sterile solution for intravenous injection. It is administered by a healthcare professional, typically as a slow infusion over several minutes. The exact rate and volume depend on the prescribed dose and patient-specific factors, and the injection site should be monitored for any local reactions.

Serious adverse reactions, though rare, include severe allergic responses such as anaphylaxis, Stevens‑Johnson syndrome, significant mood changes like depression or suicidal thoughts, and hematologic abnormalities such as low blood cell counts. Patients should be monitored closely for any signs of these conditions, and treatment should be discontinued if they occur.

Keppra is contraindicated in patients with known hypersensitivity to levetiracetam or any component of the formulation. Caution is also advised for individuals with severe renal impairment who may require dose adjustment, and for those with a history of psychiatric disorders, as they may be more susceptible to mood‑related side effects.